MTOR and neoplasm: Concurrent use of mTOR inhibitors such as rapamycin and RAD001 and standard-of-care cisplatin/radiation therapy (CRT) has been applied in HPV(+) HNSCC and CCSCC tumour xenografts and mouse models for evaluating the preclinical efficacy of mTOR inhibition [77,84].